HLA-B*5701 screening for hypersensitivity to abacavir
The purine analogues abacavir
and didanosine increase acetaminophen-induced hepatotoxicity by enhancing mitochondrial dysfunction J Antimicrob Chemother.
The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents believes stavudine, zidovudine, abacavir
, efavirenz, and all ritonavir-boosted PIs can send lipids awry and so pose a cardiovascular threat to people taking those drugs (see Table 2 in the first review article in this issue).
Although there are no available clinical trial data involving children initiating ART with once-daily dosing of abacavir
and lamivudine, the inclusion of this dosing option is supported by pharmacokinetic studies on clinically stable children aged 3-12 years with low viral loads, who were switched from twice-daily to once-daily dosing.
In addition, some studies have found abacavir
to be associated with a higher risk of acute myocardial infarction.
In the six studies showing increased risk of MI with short-term abacavir
, patients tended to be older (in their mid-40s) than the patients in the three negative studies (mid- to late 30s), she noted.
Although DAD cohort data suggested an association between abacavir
and myocardial infarction, with an increase in inflammatory markers postulated from the SMART dataset, randomised trials have failed to show this effect.
hypersensitivity and HLA-B*5701, and carbamazepine-induced Stevens-Johnson syndrome and HLA-B*1502.
The recommended combinations of NRTIs in the guidelines include the fixed-dose combinations of tenofovir and emtricitabine or abacavir
A separate study in The Lancet found that regimens containing abacavir
, the active ingredient in Epzicom, raised the risk of heart attack.
is sold by GlaxoSmithKline under the brand name Ziagen, but it is also an ingredient in Kivexa and Trizivir.
A study in Australia showed that a genetic test was very effective in predicting which patient would react badly to abacavir
Cipla (India), Ranbaxy (India), Strides Arcolab (India) and Aspen Pharmacare (South Africa)- relying on supply of active pharmaceutical ingredients from Matrix Laboratories (India)-will offer the ARV efavirenz for $240 per patient per year, and Cipla will offer the ARV abacavir
sulfate to Zonisamide, this updated guide includes monographs on some 4,700 prescription, over-the-counter, and investigational drugs.
Each day, half the volunteers received one pill containing efavirenz and another containing abacavir